CHEYENNE CLAYSON: Open Payments
NPI 1306339197 · FORT COLLINS, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,511 in 113 payments from 16 companies in 2025. Trend: 2023 $1,240 · 2024 $2,078 · 2025 $2,511
Food & beverage: $2,511
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $486 |
| Gilead Sciences, Inc. | 17 | $486 |
| Janssen Biotech, Inc. | 13 | $288 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $241 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $223 |
| Madrigal Pharmaceuticals | 7 | $191 |
| QOL Medical, LLC | 7 | $122 |
| Regeneron Healthcare Solutions, Inc. | 5 | $112 |
| GENZYME CORPORATION | 4 | $112 |
| Lilly USA, LLC | 3 | $65 |
Products named: TREMFYA, XIFAXAN, DUPIXENT, RINVOQ, REZDIFFRA, LINZESS, ENTYVIO, Sucraid.
Industry payments across CO — which companies pay providers there.
